What is the linear‑quadratic (LQ) model?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is the Linear-Quadratic (LQ) Model?

The linear-quadratic (LQ) model is a mathematical formula that describes the relationship between radiation dose and cell survival, expressed as S = e^-(αd+βd²), where α represents the linear component of cell killing and β represents the quadratic component, with the α/β ratio determining tissue sensitivity to fractionation changes 1, 2.

Core Mathematical Framework

The LQ model uses two key parameters:

  • α (alpha): The linear term representing single-hit cell killing
  • β (beta): The quadratic term representing multi-hit cell killing through accumulated sublethal damage
  • α/β ratio: Determines the relative weighting of each component and thus the sensitivity of irradiated tissue to dose fractionation 1

The formula calculates cell survival as: Surviving fraction = e^-(αd+βd²), where d is the radiation dose in Gray 2.

Clinical Application: Biologically Effective Dose (BED)

The LQ model is primarily used to calculate the biologically effective dose (BED) for different fractionation schemes using the formula: BED = D [1 + d/(α/β)], where:

  • D = total dose
  • d = fractional dose (dose per fraction)
  • α/β = tissue-specific ratio 2

This allows clinicians to compare different radiation fractionation schedules and predict equivalent biological effects. For example, using an α/β value of 10, regimens of 15-16 Gy/1F or 20 Gy/2F are comparable to the clinical standard of 30 Gy/10F 2.

Practical Use in Radiation Oncology

The LQ model guides treatment decisions for:

  • Hypofractionation planning: Determining appropriate dose-per-fraction when using fewer, larger doses 1
  • Comparing treatment regimens: Standardizing different fractionation schemes across clinical trials 2
  • Tissue-specific planning: Different tissues have different α/β ratios (prostate cancer typically uses α/β = 1.5-3 Gy, while late-responding normal tissues use α/β = 3 Gy) 1

Important Limitations and Caveats

The LQ model has significant limitations that clinicians must recognize:

  • High-dose inaccuracy: The model tends to overestimate cell killing at very high doses (>13 Gy per fraction), making it less reliable for stereotactic radiosurgery planning 2
  • α/β variability: The α/β ratio is not entirely consistent across different tumor types and cell subtypes, introducing uncertainty in BED calculations 2
  • Negative β problem: When fitted to certain datasets, the model can produce negative β values, yielding unrealistic predictions 3

Some researchers argue the LQ model is unsuitable for high-dose irradiation where the dose-survival curve significantly shifts, accounting for decreased predictive accuracy 2.

Mechanistic Interpretation

While historically the LQ model was viewed as an empirical fit, recent evidence suggests mechanistic underpinnings related to DNA damage repair pathways and cellular response heterogeneity 4, 5. The linear component (α) represents irreparable lethal lesions, while the quadratic component (β) represents potentially repairable sublethal damage that becomes lethal when accumulated 6.

When to Exercise Caution

Use alternative models or exercise extreme caution when:

  • Planning single-fraction doses >13-15 Gy (stereotactic treatments)
  • Dealing with highly radioresistant tumors where standard α/β assumptions may not apply
  • Treating melanoma or other tumors with radiation-resistant genes (TopBP1, Claspin) that alter standard dose-response relationships 2

The model remains the dominant tool in radiation biology despite these limitations, but clinicians should understand it provides approximations rather than absolute predictions 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.